Takeda Extends PRA Alliance To Japan With New JV
Takeda is setting up a new joint venture in Japan to extend its global clinical development partnership with PRA, as part of an ongoing R&D overhaul.
You may also be interested in...
The contract services industry is reaping the rewards of a resilient biotech funding environment, re-accelerating growth in the sector.
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.
Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.